Charles River Laboratories International (CRL) Stock

Investors feel positive about CRL stock because of its promising RMS potential and its efforts for growth through acquisitions.

CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is greater than the decline in revenues from the DSA segment.

While the revenue and earnings per share (EPS) for Charles River (CRL) provide insight into its performance for the quarter ending September 2024, it could be helpful to look at how these important figures stack up against Wall Street predictions and last year's results.

Charles River Laboratories (CRL) reported quarterly earnings of $2.59 per share, which is higher than the Zacks Consensus Estimate of $2.43 per share. This is a decrease compared to earnings of $2.72 per share from the same period last year.

Charles River (CRL) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories has announced the date for their third-quarter 2024 earnings release and conference call.

Charles River and Lundbeck have made a deal to use Logica in order to help discover new neurological medications.

STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical firm using its unique HyNap™ technology to create better cancer treatments, has reported important advancements after a successful meeting with the U.S. Food and Drug Administration (FDA). The company intends to resubmit its New Drug Application (NDA) for Dasynoc in the fourth quarter of 2024, taking into account the feedback from the Complete Response Letter (CRL) received from the FDA in July 2024. If the FDA establishes a timeline.

Charles River is working together with CEBINA on the DanubeNeuro program to promote new ideas in the field of neurodegeneration.